It’s a pleasure to share with you our latest report on Idiopathic Pulmonary Fibrosis (IPF)—a field rapidly evolving amidst unmet needs, increasing prevalence, and a surge in innovation.

This report delivers a strategic view of the clinical, commercial, and R&D shifts shaping the IPF landscape, tailored for leaders driving decisions in respiratory and rare diseases.

Key highlights of the presentation are:

• The evolving treatment paradigm beyond antifibrotics—toward targeted, multi-pathway, and regenerative therapies

• Strategic insights on Phase 2 & 3 assets—differentiation drivers and partnering implications

• The growing momentum in inhaled delivery and symptom-targeting approaches (e.g., anti-cough agents)
• Advances in biomarker discovery—enabling personalization and pipeline acceleration
• Competitive and partnership dynamics signalling where investor and pharma interest is heading

You can download the presentation here (also attached).